A Phase I, Open-label, Dose Escalation Study to Assess the Safety and Tolerability of FP253 in Combination With Fludarabine Phosphate.
Phase of Trial: Phase I
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Fludarabine; FP 253
- Indications Prostate cancer
- Focus Adverse reactions
- Acronyms FP253-GDEPT
- 10 Jun 2017 Biomarkers information updated
- 08 Jul 2011 Planned end date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
- 24 Mar 2010 Planned end date changed from 1 Dec 2009 to 1 Dec 2011 as reported by ClinicalTrials.gov.